Submit Deal

TEKLA CAPITAL MANAGEMENT LLC

HQ - Boston

Summary

Tekla Capital Management is a registered investment adviser based in Boston, Massachusetts and is the investment adviser for four closed-end funds.

Deals Overview

Total Deals17

Valued Deals15

Total Value£ 1.64 B

Avg. Deal Size£ 109 M

Market Context

Senior Management

Daniel R. Omstead
President and CEO

Investment Criteria

Target Equity Check-

Fund CurrencyUSD

Total funds raisedn/a

Investment Strategies

Growth

PIPE

Geographic Preferences

Canada

Mexico

United States

Industry Preferences

Food Producers

Telecommunications Equipment

Energy and Power

Renewable Energy

Banks

Finance and Credit Services

Insurance

Health Care Providers

Medical Equipment and Services

Pharmaceuticals and Biotechnology

Technology Hardware and Equipment

General Industrials

Industrial Metals and Mining

Precious Metals and Mining

Real Estate Investment and Services

Real Estate Investment Trusts

Technology

Sort

09 Jun 2016|United States|Pharmaceuticals

Target: AFFERENT PHARMACEUTICALS INC

Bidder: MERCK & CO

1 Service Providers

1 Target

3 Dealmakers

3 Target

n/a

Value

19 May 2020|United States|Pharmaceuticals

Target: RALLYBIO

Bidder: PIVOTAL BIOVENTURE PARTNERS LLC

14 Service Providers

2 Target | 12 Bidder

28 Dealmakers

3 Target | 25 Bidder

£ 119 M

Value

15 Oct 2020|Switzerland|Biotechnology

Target: VECTIVBIO

Bidder: CORMORANT ASSET MANAGEMENT

16 Service Providers

3 Target | 13 Bidder

35 Dealmakers

16 Target | 21 Bidder

£ 84 M

Value

02 Apr 2020|France|Biotechnology

Target: DYNACURE

Bidder: KURMA PARTNERS

9 Service Providers

3 Target | 6 Bidder

8 Dealmakers

2 Target | 6 Bidder

£ 41 M

Value

30 Mar 2021|United States|Biotechnology

Target: PYXIS ONCOLOGY

Bidder: RTW INVESTMENTS

5 Service Providers

2 Target | 3 Bidder

5 Dealmakers

2 Target | 3 Bidder

£ 110 M

Value

04 May 2021|Switzerland|Pharmaceuticals

Target: OCULIS

Bidder: TEKLA CAPITAL MANAGEMENT LLC

13 Service Providers

2 Target | 11 Bidder

18 Dealmakers

5 Target | 13 Bidder

£ 40 M

Value

09 Nov 2021|United States|Pharmaceuticals

Target: ARBOR BIOTHECHNOLOGIES

Bidder: TCG CROSSOVER

4 Service Providers

2 Target | 2 Bidder

5 Dealmakers

3 Target | 2 Bidder

£ 159 M

Value

04 Oct 2021|Switzerland|Biotechnology

Target: MOONLAKE IMMUNOTHERAPEUTICS

Bidder: BVF PARTNERS

25 Service Providers

7 Target | 18 Bidder

44 Dealmakers

11 Target | 34 Bidder

£ 169 M

Value

29 Nov 2021|United Kingdom|Biotechnology

Target: QUELL THERAPEUTICS

Bidder: JANUS HENDERSON INVESTORS

7 Service Providers

3 Target | 4 Bidder

12 Dealmakers

6 Target | 6 Bidder

£ 117 M

Value

29 Nov 2021|United States|Biotechnology

Target: HOTSPOT THERAPEUTICS

Bidder: SOFINNOVA PARTNERS

10 Service Providers

2 Target | 8 Bidder

11 Dealmakers

3 Target | 8 Bidder

£ 74 M

Value

07 Feb 2022|United States|Biotechnology

Target: ENDEAVOR BIOMEDICINES

Bidder: ALLY BRIDGE GROUP

10 Service Providers

2 Target | 8 Bidder

11 Dealmakers

3 Target | 8 Bidder

£ 74 M

Value

10 May 2022|United States|Pharmaceuticals

Target: INVETX

Bidder: F-PRIME CAPITAL

10 Service Providers

3 Target | 7 Bidder

13 Dealmakers

6 Target | 7 Bidder

£ 49 M

Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy